Achieving a malaria-free world presents exciting scientific challenges as well as
overwhelming health, equity, and economic benefits. WHO and countries are setting …

In 2013 there were an estimated 584,000 deaths and 198 million clinical illnesses due to
malaria, the majority in sub-Saharan Africa. Vaccines would be the ideal addition to the …

A highly protective malaria vaccine would greatly facilitate the prevention and elimination of
malaria and containment of drug-resistant parasites. A high level (more than 90%) of …

The global decline in malaria has stalled, emphasizing the need for vaccines that induce
durable sterilizing immunity. Here we optimized regimens for chemoprophylaxis vaccination …

Background WHO recently approved a partially effective vaccine that reduces clinical
malaria in children, but increased vaccine activity is required to pursue malaria elimination …

Sanaria Inc. has developed methods to manufacture, purify and cryopreserve aseptic
Plasmodium falciparum (Pf) sporozoites (SPZ), and is using this platform technology to …

We are using controlled human malaria infection (CHMI) by direct venous inoculation (DVI)
of cryopreserved, infectious Plasmodium falciparum (Pf) sporozoites (SPZ)(PfSPZ …

Controlled human malaria infection (CHMI) entails deliberate infection with malaria
parasites either by mosquito bite or by direct injection of sporozoites or parasitized …

Immunization with radiation-attenuated Plasmodium falciparum (Pf) sporozoites (SPZ) in
PfSPZ Vaccine, has provided better vaccine efficacy (VE) against controlled human malaria …

Affinity maturation, the clonal selection and expansion of antigen-activated B cells
expressing somatically mutated antibody variants that develop during T cell–dependent …